Timing of Coronary Artery Bypass Surgery Among Patients With Acute Coronary Syndromes Initially o… (NCT02668562) | Clinical Trial Compass
CompletedNot Applicable
Timing of Coronary Artery Bypass Surgery Among Patients With Acute Coronary Syndromes Initially on Ticagrelor
Canada143 participantsStarted 2016-02
Plain-language summary
Ticagrelor, a more potent P2Y12 inhibitor, has been shown to reduce major adverse cardiac events (MACE) in acute coronary syndromes (ACS). It is increasingly used as a first line therapy in ACS. However, more potent P2Y12 inhibition has been associated with increased bleeding. This may be of particular concern for patients with ACS who require coronary artery bypass surgery (CABG). In particular, the timing for cessation of ticagrelor before proceeding to CABG is unclear. RAPID TITRATE CABG is a randomized vanguard study to evaluate the feasibility and preliminary safety of a strategy of early versus delayed CABG in ACS patients initially treated with ticagrelor and to identify potential mechanisms underlying benefits or complications of early bypass surgery.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ACS patient referred for CABG and have received \>= 1 dose of ticagrelor before decision for CABG made
Exclusion Criteria:
Patients are excluded if they:
* refuse consent for enrollment
* are deemed to require immediate CABG (Day 0 or day 1)
* have a ST-elevation myocardial infarction (STEMI )initially treated with primary PCI
* are undergoing concurrent valve surgery
* are intolerant or allergic to aspirin
* have been on an oral anticoagulant (including a vitamin K antagonist or a NOAC)
* received adjuvant therapy with a glycoprotein IIbIIIa inhibitor
* have a co-morbidity with life-expectancy of \< 1 year
* have active bleeding
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Severe-massive bleeding
Timeframe: 24 hours post CABG
2
12-hour chest tube drainage
Timeframe: 12 hours post CABG
Trial details
NCT IDNCT02668562
SponsorOttawa Heart Institute Research Corporation